BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a good quality company.
The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Astrazeneca Pharma India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -12.9% | 3.8% | 18.7% | 18.7% | 26.5% | 34.6% | 31.2% | 17.4% | 24.5% | 33.9% | - |
| Value Creation Index ⓘ | -1.9 | -0.7 | 0.3 | 0.3 | 0.9 | 1.6 | 1.3 | 0.3 | 0.8 | 1.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,485 |
| Sales YoY Gr. | - | 9% | -3.6% | 5% | 27.6% | 14.2% | -2.2% | -1% | 24.5% | 29.2% | - |
| Adj EPS ⓘ | -8.4 | 2.2 | 5.9 | 10.5 | 21.6 | 28.9 | 36.9 | 23.9 | 50.2 | 60.1 | 32.8 |
| YoY Gr. | - | NA | 171.6% | 76.5% | 106.5% | 34.1% | 27.4% | -35.2% | 110.1% | 19.8% | - |
| BVPS (₹) ⓘ | 60.3 | 62.4 | 88.5 | 97.9 | 119.5 | 145.1 | 181.8 | 203.8 | 234.5 | 283.5 | 271.7 |
| Adj Net Profit ⓘ | -21 | 5.5 | 14.8 | 26.1 | 54 | 72.3 | 92.2 | 59.7 | 126 | 150 | 82 |
| Cash Flow from Ops. ⓘ | -45.7 | 57 | 38.1 | 8.8 | 55 | 87.4 | 105 | 101 | 58.3 | 27.9 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 10.7% | 12.2% | 16.8% | 29.2% | ||||
| Adj EPS ⓘ | NA | 22.8% | 17.7% | 19.8% | ||||
| BVPSⓘ | 18.8% | 18.9% | 16% | 20.9% | ||||
| Share Price | 22.9% | 20.9% | 30.4% | 47.1% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -13 | 3.6 | 7.8 | 11.1 | 19.7 | 21.7 | 22.5 | 12.3 | 22.8 | 23.1 | 11.8 |
| Op. Profit Mgn % ⓘ | -2.6 | 3 | 6.9 | 8.2 | 9.8 | 14.6 | 16.7 | 10.7 | 16.5 | 14.3 | 10.4 |
| Net Profit Mgn % ⓘ | -4.1 | 1 | 2.7 | 4.6 | 7.4 | 8.7 | 11.3 | 7.4 | 12.5 | 11.6 | 5.5 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 173 | 167 | 185 | 216 | 176 | 167 | 193 | 200 | 185 | 179 | 114 |
| Cash Conv. Cycle ⓘ | 11 | 17 | 11 | 12 | 0 | -2 | -1 | 6 | 4 | 23 | 66 |
Sales growth is growing at healthy rate in last 3 years 16.78%
Net Profit is growing at healthy rate in last 3 years 17.73%
Sales growth is good in last 4 quarters at 29.83%
Return on Equity has declined versus last 3 years average to 11.80%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 32.8 | - |
| TTM Sales (₹ Cr.) | 1,485 | - |
| BVPS (₹.) ⓘ | 271.7 | - |
| Reserves (₹ Cr.) ⓘ | 674 | - |
| P/BV ⓘ | 24.81 | - |
| PE ⓘ | 205.71 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 4050.15 / 8139.85 |
| All Time Low / High (₹) | 9.00 / 8139.85 |
| Market Cap (₹ Cr.) | 16,852 |
| Equity (₹ Cr.) | 5 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43.1 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 |
| Operating Expenses ⓘ | 531 | 547 | 507 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 |
| Manufacturing Costs | 26 | 33 | 44 | 59 | 58 | 49 | 57 | 65 | 82 | 94 |
| Material Costs | 194 | 195 | 171 | 178 | 227 | 300 | 287 | 305 | 355 | 590 |
| Employee Cost | 160 | 169 | 162 | 150 | 197 | 217 | 220 | 230 | 259 | 241 |
| Other Costs ⓘ | 150 | 150 | 129 | 137 | 175 | 146 | 115 | 119 | 142 | 185 |
| Operating Profit ⓘ | -14 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 |
| Operating Profit Margin (%) | -2.6% | 2.9% | 6.8% | 8.1% | 9.8% | 14.5% | 16.7% | 10.7% | 16.5% | 14.2% |
| Other Income ⓘ | 8 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | 26 | 35 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -40 | 16 |
| Profit Before Tax ⓘ | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 |
| Tax ⓘ | 0 | 1 | 15 | 18 | 18 | 42 | 34 | 21 | 35 | 58 |
| Profit After Tax | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 |
| PAT Margin (%) | -4.0% | 0.9% | 3.7% | 4.5% | 7.5% | 8.7% | 11.5% | 7.6% | 9.9% | 12.5% |
| Adjusted EPS (₹) | -8.3 | 2.1 | 8.0 | 10.4 | 21.8 | 28.9 | 37.3 | 24.6 | 39.7 | 64.6 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 151 | 156 | 221 | 245 | 299 | 363 | 455 | 509 | 586 | 709 |
| Share Capital ⓘ | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves ⓘ | 146 | 151 | 216 | 240 | 294 | 358 | 450 | 504 | 581 | 704 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Payables | 111 | 95 | 88 | 127 | 168 | 210 | 178 | 190 | 228 | 197 |
| Others Liabilities ⓘ | 150 | 178 | 205 | 203 | 124 | 203 | 241 | 277 | 328 | 372 |
| Total Liabilities ⓘ | 412 | 429 | 514 | 575 | 591 | 776 | 874 | 977 | 1,142 | 1,277 |
Fixed Assets | ||||||||||
| Gross Block | 191 | 204 | 103 | 106 | 120 | 133 | 160 | 169 | 179 | 187 |
| Accumulated Depreciation | 90 | 106 | 16 | 30 | 45 | 61 | 79 | 94 | 110 | 120 |
| Net Fixed Assetsⓘ | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 |
| CWIP ⓘ | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 86 | 77 | 58 | 113 | 118 | 165 | 160 | 140 | 190 | 228 |
| Trade Receivables | 43 | 83 | 43 | 55 | 80 | 83 | 85 | 86 | 108 | 153 |
Cash Equivalents  ⓘ
| 25 | 77 | 116 | 126 | 173 | 253 | 352 | 448 | 500 | 506 |
| Others Assetsⓘ | 144 | 89 | 206 | 203 | 138 | 179 | 192 | 226 | 274 | 323 |
| Total Assets ⓘ | 412 | 429 | 514 | 575 | 591 | 776 | 874 | 977 | 1,142 | 1,277 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 |
| PBT ⓘ | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 |
| Adjustment ⓘ | 9 | 12 | 15 | 3 | 8 | 10 | 14 | 10 | -5 | -7 |
| Changes in Working Capital ⓘ | -33 | 42 | -0 | -34 | 10 | -3 | -4 | 33 | -30 | -128 |
| Tax Paid ⓘ | -1 | -3 | -12 | -4 | -35 | -34 | -33 | -25 | -41 | -56 |
| Cash Flow From Investing Activity ⓘ | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 |
| Capex | -24 | -9 | -5 | -6 | -18 | -14 | -5 | -6 | -5 | -10 |
| Net Investments | 0 | 0 | 0 | -11 | 12 | -169 | 169 | 0 | 0 | 0 |
| Others ⓘ | 5 | 5 | 6 | 8 | 11 | 12 | 9 | 11 | 23 | 32 |
| Cash Flow From Financing Activityⓘ | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | -3 | -5 | -5 | -20 | -40 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | -3 | -3 | -4 | -4 | -4 |
| Net Cash Flow ⓘ | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -12.93 | 3.43 | 10.63 | 11.12 | 20.03 | 21.83 | 22.83 | 12.78 | 18.13 | 24.95 |
| ROCE (%) | -12.93 | 3.76 | 18.74 | 18.65 | 26.53 | 34.61 | 31.24 | 17.36 | 24.49 | 33.94 |
| Asset Turnover Ratio | 1.27 | 1.36 | 1.16 | 1.05 | 1.25 | 1.22 | 0.99 | 0.87 | 0.95 | 1.08 |
| PAT to CFO Conversion(x) | N/A | 11.4 | 1.9 | 0.35 | 1.02 | 1.21 | 1.13 | 1.63 | 0.59 | 0.17 | Working Capital Days |
| Receivable Days | 33 | 40 | 42 | 31 | 34 | 36 | 38 | 39 | 35 | 37 |
| Inventory Days | 63 | 52 | 45 | 55 | 58 | 62 | 73 | 68 | 60 | 59 |
| Payable Days | 208 | 193 | 194 | 220 | 238 | 230 | 247 | 220 | 215 | 131 |
Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.
The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.
The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.
The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.
Business area of the company
The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.
Core Therapy Areas
Milestones and achievements
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
